Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells

Molecular Oncology

Volumn 7, Issue 6, 2013, Pages 1043-1055

  Liu, Jia ^b   Ma, Leina ^c   Li, Caixin ^a   Zhang, Ziyu ^a   Yang, Guanghua ^a,d   Zhang, Wenwei ^a,e  

^a Telebio Biomedical Co Ltd   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c OCEAN UNIVERSITY OF CHINA   (China)

^d TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^e BICÊTRE HOSPITAL   (France)

Author keywords

Adenovirus; miRNA; TRAIL; Uveal melanoma

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; LUCIFERASE; MICRORNA; MICRORNA 137; MICRORNA 182; MICRORNA 34A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG POTENCY; DRUG SPECIFICITY; ENZYME ACTIVITY; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UVEA MELANOMA;

ADENOVIRIDAE; ANIMALIA;

ADENOVIRUS; MIRNA; TRAIL; UVEAL MELANOMA;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; RNA, NEOPLASM; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC; UVEAL NEOPLASMS;

EID: 84887995344     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.08.003     Document Type: Article

References (43)

1. Alizadeh H., Howard K., Mellon J., Mayhew E., Rusciano D., Niederkorn J.Y. Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer. Invest. Ophthalmol. Vis. Sci. 2003, 44:3042-3051.
2. Armeanu S., Lauer U.M., Smirnow I., Schenk M., Weiss T.S., Gregor M., Bitzer M. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res. 2003, 63:2369-2372.
3. Bakalian S., Marshall J.C., Logan P., Faingold D., Maloney S., Di Cesare S., Martins C., Fernandes B.F., Burnier M.N. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin. Cancer Res. 2008, 14:951-956.
4. Bo Y., Guo G., Yao W. MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth. J.Neurooncol. 2013, 112:27-37.
5. Carlo-Stella C., Lavazza C., Locatelli A., Vigano L., Gianni A.M., Gianni L. Targeting TRAIL agonistic receptors for cancer therapy. Clin. Cancer Res. 2007, 13:2313-2317.
6. Carlring J., Shaif-Muthana M., Sisley K., Rennie I.G., Murray A.K. Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses. Immunology 2003, 109:41-48.
7. Chen Q., Lou W., Shen J., Ma L., Yang Z., Liu L., Luo J., Qian C. Potent antitumor activity in experimental hepatocellular carcinoma by adenovirus-mediated coexpression of TRAIL and shRNA against COX-2. Clin. Cancer Res. 2010, 16:3696-3705.
8. Chen X., Wang J., Shen H., Lu J., Li C., Hu D.N., Dong X.D., Yan D., Tu L. Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2011, 52:1193-1199.
9. Corazza N., Jakob S., Schaer C., Frese S., Keogh A., Stroka D., Kassahn D., Torgler R., Mueller C., Schneider P., Brunner T. TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J.Clin. Invest. 2006, 116:2493-2499.
10. Cun B., Song X., Jia R., Zhao X., Wang H., Ge S., Fan X. Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block. Cancer Biol. Ther. 2012, 13:77-84.
11. Huang X., Jia R., Zhao X., Liu B., Wang H., Wang J., Zhou Y., Cun B., Ge S., Fan X. Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines. Br. J. Ophthalmol. 2012, 96:1331-1338.
12. Huang X., Wang L., Zhang H., Wang H., Zhao X., Qian G., Hu J., Ge S., Fan X. Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors. PLoS One 2012, 7:e44301.
13. Huang Y., Sheikh M.S. TRAIL death receptors and cancer therapeutics. Toxicol. Appl. Pharmacol. 2007, 224:284-289.
14. Jiang G., Zhang K., Jiang A.J., Xu D., Xin Y., Wei Z.P., Zheng J.N., Liu Y.Q. A conditionally replicating adenovirus carrying interleukin-24 sensitizes melanoma cells to radiotherapy via apoptosis. Mol. Oncol. 2012, 6:383-391.
15. Jin H., Lv S., Yang J., Wang X., Hu H., Su C., Zhou C., Li J., Huang Y., Li L., Liu X., Wu M., Qian Q. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells. PLoS One 2011, 6:e21307.
16. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., Strom S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 2000, 6:564-567.
17. Kozaki K., Imoto I., Mogi S., Omura K., Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008, 68:2094-2105.
18. Li H., Niederkorn J.Y., Neelam S., Alizadeh H. Resistance and susceptibility of human uveal melanoma cells to TRAIL-induced apoptosis. Arch. Ophthalmol. 2005, 123:654-661.
19. Liang L., Li X., Zhang X., Lv Z., He G., Zhao W., Ren X., Li Y., Bian X., Liao W., Liu W., Yang G., Ding Y. MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMNL2. Gastroenterology 2013, 144:624-635 e624.
20. Liu C., Sun B., An N., Tan W., Cao L., Luo X., Yu Y., Feng F., Li B., Wu M., Su C., Jiang X. Inhibitory effect of survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer. Mol. Oncol. 2011, 5:545-554.
21. Liu M., Lang N., Qiu M., Xu F., Li Q., Tang Q., Chen J., Chen X., Zhang S., Liu Z., Zhou J., Zhu Y., Deng Y., Zheng Y., Bi F. miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int. J. Cancer 2011, 128:1269-1279.
22. Lub-de Hooge M.N., de Vries E.G., de Jong S., Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2005, 64:854-858.
23. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482:347-355.
24. Luo J., Xia Q., Zhang R., Lv C., Zhang W., Wang Y., Cui Q., Liu L., Cai R., Qian C. Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin. Cancer Res. 2008, 14:2450-2457.
25. Ma D., Gerard R.D., Li X.Y., Alizadeh H., Niederkorn J.Y. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 1997, 90:2738-2746.
26. Ma L., Liu J., Shen J., Liu L., Wu J., Li W., Luo J., Chen Q., Qian C. Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol. Ther. 2010, 9:554-561.
27. Ozoren N., Kim K., Burns T.F., Dicker D.T., Moscioni A.D., El-Deiry W.S. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2000, 60:6259-6265.
28. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277:815-818.
29. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
30. Poell J.B., van Haastert R.J., de Gunst T., Schultz I.J., Gommans W.M., Verheul M., Cerisoli F., van Noort P.I., Prevost G.P., Schaapveld R.Q., Cuppen E. A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability. PLoS One 2012, 7:e43569.
31. Ren D.H., Mayhew E., Hay C., Li H., Alizadeh H., Niederkorn J.Y. Uveal melanoma expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and susceptibility to TRAIL-induced apoptosis. Invest. Ophthalmol. Vis. Sci. 2004, 45:1162-1168.
32. Silber J., Lim D.A., Petritsch C., Persson A.I., Maunakea A.K., Yu M., Vandenberg S.R., Ginzinger D.G., James C.D., Costello J.F., Bergers G., Weiss W.A., Alvarez-Buylla A., Hodgson J.G. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008, 6:14.
33. Sontheimer E.J., Carthew R.W. Silence from within: endogenous siRNAs and miRNAs. Cell 2005, 122:9-12.
34. Wang B., Liu J., Ma L.N., Xiao H.L., Wang Y.Z., Li Y., Wang Z., Fan L., Lan C., Yang M., Hu L., Wei Y., Bian X.W., Chen D., Wang J. Chimeric 5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44(+) gastric cancer cells via attenuating Wnt signaling. J.Gastroenterol. 2012.
35. Woodman S.E. Metastatic uveal melanoma: biology and emerging treatments. Cancer J. 2012, 18:148-152.
36. Yan D., Dong X.D., Chen X., Yao S., Wang L., Wang J., Wang C., Hu D.N., Qu J., Tu L. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS One 2012, 7:e40967.
37. Yan D., Zhou X., Chen X., Hu D.N., Dong X.D., Wang J., Lu F., Tu L., Qu J. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest. Ophthalmol. Vis. Sci. 2009, 50:1559-1565.
38. Zhang Y., Fang L., Zhang Q., Zheng Q., Tong J., Fu X., Jiang X., Su C., Zheng J. An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I(131)-metuximab in hepatocellular carcinoma. Mol. Oncol. 2012.
39. Zhao Y., Li Y., Lou G., Zhao L., Xu Z., Zhang Y., He F. MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One 2012, 7:e39102.
40. Zhao Y., Li Y., Wang L., Yang H., Wang Q., Qi H., Li S., Zhou P., Liang P., Wang Q., Li X. microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer. J.Exp. Clin. Cancer Res. 2013, 32:10.
41. Zhao Y., Li Y., Wang Q., Wang L., Yang H., Li M. Increased antitumor capability of fiber-modified adenoviral vector armed with TRAIL against bladder cancers. Mol. Cell Biochem. 2011, 353:93-99.
42. Zhou Y., Song X., Jia R., Wang H., Dai L., Xu X., Gu P., Ge S., Fan X. Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma. Pigment Cell Melanoma Res. 2010, 23:661-674.
43. Zhu X., Li Y., Shen H., Li H., Long L., Hui L., Xu W. miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Lett. 2013, 587:73-81.